Loader
research-image

Research & Clinical Trials

In Raffles Cancer Centre, we actively seek partnerships with research organisations who share our passion in our mission to provide the best cancer care for our patients. Clinical trials constitute an integral component of patient management in Raffles Hospital. Through these trials, our patients have access to novel therapeutic agents, which have yet made available in the market,  will give hope even after their conditions have failed to respond to standard lines of treatment.

Our specialists in Raffles Cancer Centre have abundant experience as principal investigators and co-investigators of well over 50 clinical trials in various phases (phase I, II, III), both investigator-initiated and pharmaceutical company-initiated, and as part of larger international multi-centre phase III trials.

Coordinated by the Hospital ‘s Clinical Trial Unit, these trials help expand the treatment options available to patients.

All clinical trials involving humans are subjected to approval by the Hospital’s Institutional Review Board (IRB) which ensures all clinical trials are ethically acceptable and that the rights, safety and well –being of the patients are safeguarded at all times. The IRB also monitors the conduct of the clinical trials and ensures that they are in compliance with Good Clinical Practice on an ongoing basis.

No.

Indication

Study Information

Investigator

Status

1

Lung Cancer

Advanced non-small cell lung cancer (ALK Positive) –First line

Dr Lynette Ngo

Recruiting

2

Lymphoma

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

Dr Daryl Tan

Recruiting

3

Thrombotic

Microangiopa thies

Atypical hemolytic uremic syndrome (aHUS), thrombotic

thrombocytopenic purpura (TTP), or hematopoietic stem cell transplant (HSCT)-associated TMA.

Dr Daryl Tan

Recruiting

4

Colorectal Cancer

Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC).

Dr Donald Poon

Recruiting

5

Gastric Cancer

Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

Dr Donald Poon

Recruiting

6

B-cell lymphoma

Transplant-eligible relapsed/refractory diffuse large B-cell lymphoma in patients not achieving a complete response at pre-transplant

interim assessment.

Dr Daryl Tan

Recruiting

7

Non- Hodgkin’s lymphoma (iNHL)

Relapsed indolent Non-Hodgkin’s lymphoma, after 1-3 lines of treatment.

Dr Daryl Tan

Recruiting

8

Internal Hemorrhoids

Instalief Hemorrhoids Treatment for patients with Grade 1 or 2 internal hemorrhoids.

Dr Wong Kutt Sing

Recruiting

9

Gastric Cancer

Maintainence Therapy in patients with Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy

Dr Lynette Ngo

Upcoming

10

Solid Tumours

Locally advanced or metastatic melanoma, non-small cell lung cancer, urothelial carcinoma or other solid tumors.

Dr Chin Tan Min

Upcoming

11

NPC

Immunotherapy Combined with Chemotherapy versus Placebo

Combined with Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer

Dr Chin Tan Min

Upcoming

12

Ovarian Cancer

Immunotherapy in Combination with Chemotherapy followed by

maintenance therapy in patients with previously untreated advanced ovarian cancer

Dr Lynette Ngo

Upcoming

For more information, please contact:

Raffles Hospital Clinical Trials Unit
Mon - Fri: 9.00am to 5.00pm
Tel: +65 6311 2305
Emailyang_christie@rafflesmedical.com

Your participation in this research study is purely voluntary. You may withdraw your participation at any phase during the study.

Update July 2017